SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-24-018143
Filing Date
2024-04-25
Accepted
2024-04-25 16:02:41
Documents
15
Period of Report
2024-06-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A crdf-20240425.htm   iXBRL DEF 14A 860317
6 crdf-20240425_g1.jpg GRAPHIC 57091
  Complete submission text file 0001628280-24-018143.txt   1702763

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT crdf-20240425.xsd EX-101.SCH 4688
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT crdf-20240425_def.xml EX-101.DEF 6118
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT crdf-20240425_lab.xml EX-101.LAB 9991
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT crdf-20240425_pre.xml EX-101.PRE 5749
18 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20240425_htm.xml XML 158371
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

IRS No.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35558 | Film No.: 24876113
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)